Loading...
Loading...
Antares Pharma, Inc.
ATRS today announced the approval of OTREXUP^™
(methotrexate) injection by the U.S. Food and Drug Administration (FDA).
OTREXUP^™ is the first FDA approved subcutaneous (SC) methotrexate (MTX) for
once weekly self-administration with an easy-to-use, single dose, disposable
auto injector. OTREXUP^™ is indicated for adults with severe active rheumatoid
arthritis (RA) who have had an insufficient therapeutic response to or are
intolerant of an adequate trial of first line therapy including full dose
non-steroidal anti-inflammatory agents (NSAIDs), or children with active
polyarticular juvenile idiopathic arthritis (pJIA). The FDA also approved
adult use of OTREXUP^™ for symptomatic control of severe recalcitrant,
disabling psoriasis that is not adequately responsive to other forms of
therapy.
In 2012, approximately six million prescriptions were written across all
dosage forms of MTX in the U.S. to treat patients for RA, pJIA and psoriasis,
the same indications for which OTREXUP^™ has been approved. MTX treatment is
usually initiated with oral tablets, however; many patients experience an
inadequate response for reasons of efficacy or tolerability.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
We simplify the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in